Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Post-transplant monitoring of multiparameter flow-cytometry (MFC)-based measurable residual disease (MRD) assessment combined with T-cell chimerism following allogeneic stem cell transplantation (HCT) in Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS)

View Full Paper
Ask AI
Bookmark
Share

Authors

MAMajed AltarebRKRajat KumarJMJonas Mattsson

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows relapse risk stratification using MRD and T-cell chimerism in AML and MDS post-transplant.

Key Points

  • This research evaluates the prognostic impact of MRD and T-cell chimerism on relapse risk in AML and MDS after HCT.
  • Retrospective analysis of 196 AML and MDS patients undergoing allogeneic HCT.
  • Assessment of MFC-based MRD before and after HCT and T-cell chimerism at specified time points.
  • Longitudinal analysis using recursive partitioning for risk stratification of relapse-free survival.
  • D60 MFC-MRD levels showed a significant association with relapse-free survival.
  • Proportion of patients with MFC-MRD positivity decreased from 52% pre-HCT to 38.2% at D60.
  • Risk groups based on D60 MFC-MRD and D30 TCC levels effectively stratified patients and predicted relapse risk.

Cite This Study

Altareb et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5ebhttps://doi.org/10.1182/blood-2025-4295
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with <scp>MDS</scp>/<scp>AML</scp> or <scp>AML</scp>2024 · 8 citations
  2. 2Real-world heterogeneity in the prognostic value of pre-transplant flow cytometry measurable residual disease in acute myeloid leukemia in first complete remission: CIBMTR analysis2026
  3. 3Mixed T-cell chimerism at 3 months predicts late relapse in acute myeloid leukemia after allogeneic stem cell transplantation2026
  4. 4Type and degree/number of immunophenotypic abnormalities refine multiparameter flow cytometry (MFC)-based measurable residual disease (MRD) testing in adults allografted for Acute Myeloid Leukemia (AML) in morphologic remission2025
  5. 5Prognostic value of measurable residual disease in high-risk MDS after intensive chemotherapy in HOVON-SAKK studies.2026